Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia

September 29, 2006

Therapeutic drug monitoring can be used in many ways in the management of HIV-infected patients. One potential use is to reduce the standard dose of a drug in order to minimize toxicity. Alternatively, it can be used to increase a dose of a drug in order to augment efficacy. In this study, French researchers tested the strategy of reducing the dose of lopinavir/ritonavir (LPV/r, Kaletra) in patients who have plasma concentrations above the recommended target level of 3,000 ng/ml.

Patients were eligible if they were receiving a lopinavir/ritonavir, first-line antiretroviral regimen, had an HIV RNA less than 50 copies/mL, and had a measured trough concentration of lopinavir of greater than 5,000 ng/ml. Thirty-five patients were identified, 28 of whom had evaluable data. The mean baseline plasma concentration of lopinavir was 7,363 ng/ml (range 5,118 to 12,415). After reducing the dose of lopinavir/ritonavir from three soft-gel capsules twice daily to two twice daily, mean concentrations were reduced to 4,319 ng/ml (range 1,427 to 8,683).

Evolution of Parameters

A statistically significant decline in triglycerides was observed, with smaller changes in low-density lipoprotein (LDL) cholesterol. Eight of the 28 patients experienced low-level viremia (a "blip"), and three of the 28 had a viral load greater than 50 copies/mL at week 48. No resistance data were presented.

While the authors conclude that a reduced dosing of lopinavir/ritonavir is associated with a sustained virologic response, there are several important limitations to the study. First, the researchers utilized the older, soft-gel formulation of lopinavir/ritonavir, which is known to have a wider range of inter-patient variability in terms of lopinavir concentrations. Second, the occurrence of low-level viremia may be a harbinger of a greater risk of virologic breakthrough in the long run, a result that cannot be excluded in the absence of a control group and longer follow-up. Third, many HIV centers do not routinely use therapeutic drug monitoring -- it is notably uncommon in clinical practice in the United States -- and hence candidates for this strategy would be hard for many practitioners to identify. In summary, the usual dosing of lopinavir/ritonavir with the newer tablet formulation -- two tablets twice daily -- should still be the standard of care.


  1. Meynard J, Lacombe K, Poirier J, et al. Virological efficacy and impact on lipids profile of a reduced dosing (2 tablets BID) of lopinavir/ritonavir (LPV/r) in HIV infected patients. (Kaledose Trial). In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, Calif. Abstract H-1384.

It is a part of the publication 46th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.